Liprolog Mix25 Kwikpen (Insulin Lispro)

• Insulin lispro is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake.
• Type 1 diabetes mellitus: provides mealtime glucose control and reduces hyperglycaemia.
• Type 2 diabetes mellitus: improves post‑prandial glucose levels when used alone or with oral agents.
• Gestational diabetes mellitus: offers rapid insulin action when insulin therapy is required during pregnancy.

• Insulin lispro binds to the insulin receptor’s α‑subunit on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake, and suppresses hepatic gluconeogenesis. The analogue’s altered amino‑acid sequence accelerates dissociation of hexamers, yielding a rapid onset of action after subcutaneous injection.

Insulin lispro may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosage is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight with prolonged therapy.
• Lipodystrophy: localized fat tissue changes at injection sites.
• Allergic skin reactions: rash or urticaria at the site.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological impairment requiring assistance.
• Anaphylaxis: life‑threatening allergic reaction with airway compromise.
• Hypokalemia: low serum potassium levels.
• Acute insulin allergy: systemic urticaria, angioedema, or bronchospasm.
• Ketoacidosis: metabolic acidosis if insulin is omitted.

• When using Liprolog Mix25 Kwikpen, several precautions should be observed to ensure safe and effective therapy.
• Dose individualisation: adjust dose based on blood glucose monitoring and carbohydrate intake.
• Hypoglycemia risk: educate patients on recognizing and treating low blood glucose.
• Renal impairment: monitor closely and consider dose reduction in reduced kidney function.
• Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider.
• Driving and operating machinery: avoid if experiencing hypoglycemia symptoms.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid)

• Concomitant use with other insulin or sulfonylureas: may cause severe hypoglycemia.
• Alcohol consumption: can potentiate hypoglycemic episodes, especially with missed meals.
• Beta‑blockers: may mask hypoglycemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may increase blood glucose, requiring insulin dose adjustment.
• Thiazide diuretics: can raise glucose levels, necessitating monitoring.
• ACE inhibitors: may enhance insulin sensitivity, potentially leading to hypoglycemia.